56
Participants
Start Date
January 23, 2020
Primary Completion Date
August 26, 2021
Study Completion Date
February 23, 2023
VE800
VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
Nivolumab
Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
Vancomycin Oral Capsule
Vancomycin is an antibiotic used to treat or prevent infection.
New York University Medical Oncology Associates, New York
Weill Cornell Medicine, New York
UPMC Hillman Cancer Center, Pittsburgh
Moffitt Cancer Center, Tampa
Florida Cancer Specialists, Sarasota
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
The University of Chicago, Chicago
Washington University School of Medicine Siteman Cancer Center, St Louis
Baylor Scott and White Center for Advanced Heart and Lung Disese, Dallas
Huntsman Cancer Institute and Hospital, Salt Lake City
HonorHealth Research Institute, Scottsdale
University of California Los Angeles, Los Angeles
The Angeles Clinic and Research Institute - West Los Angeles Office, Santa Monica
University of California Los Angeles, Santa Monica
Pacific Hematology Oncology Associates, San Francisco
Swedish Medical Oncology - First Hill, Seattle
John Theurer Cancer Center, Hackensack
The Miriam Hospital, Providence
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Vedanta Biosciences, Inc.
INDUSTRY